GFAP and Alzheimer disease: We further assessed in vivo study after intraperitoneally injecting carprofen (25 mg/kg/day) to a female 5XFAD (B6SJL-Tg(APPSwFlLon, PSEN1*M146L*L286V) 6799Vas/Mmjax) transgenic mouse model of AD followed by staining for Aβ plaques utilizing thioflavin S (ThS) dye and detecting reactive astrocytes by glial fibrillary acidic protein (GFAP) antibody.